Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
J Dermatol. 2019 May;46(5):449-452. doi: 10.1111/1346-8138.14861. Epub 2019 Mar 25.
Anti-programmed death 1 antibody monotherapy is a first-line and widely used immunotherapy for the treatment of advanced melanoma. However, its efficacy rate is lower in the Japanese population compared with the Caucasian population. Ipilimumab is another immune checkpoint inhibitor (ICI) that activates and increases T cells, which suppress the function of regulatory T cells. Previous reports have suggested that ipilimumab is useful for treating advanced melanoma, particularly in combination with radiation therapy. In this report, we described three cases of nivolumab-resistant melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy, which may enhance the therapeutic effects of the sequential administration of ICI.
抗程序性死亡 1 抗体单药治疗是治疗晚期黑色素瘤的一线广泛应用的免疫治疗方法。然而，其疗效在日本人群中低于白种人人群。Ipilimumab 是另一种免疫检查点抑制剂（ICI），可激活并增加 T 细胞，抑制调节性 T 细胞的功能。先前的报告表明，Ipilimumab 对治疗晚期黑色素瘤有用，特别是与放射治疗联合使用。在本报告中，我们描述了三例纳武单抗耐药的黑色素瘤病例，通过强度调制放射治疗成功控制了 Ipilimumab，这可能增强 ICI 序贯给药的治疗效果。
